Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214032 · ClinicalTrials.gov registry record · Phase 2
Pycnogenol for the Treatment of Lymphedema
A Phase 2 study of Lymphedema, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT00214032 is a Phase 2 study of Lymphedema that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 2 participants, below the 9,300-participant average among 34 other Lymphedema trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00214032, a Phase 2 study of Lymphedema, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to evaluate the effectiveness of Pycnogenol (French maritime pine bark extract) for arm lymphedema in women following treatment for breast cancer, to evaluate the accuracy and sensitivity of bioelectric impedence as a measurement of lymphedema of the arm, and to validate the proposed arm lymphedema quality-of-life questionnaire.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pycnogenol
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2002-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214032
The ClinicalTrials.gov registry entry for NCT00214032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,300-participant average among 34 other Lymphedema trials with a reported enrollment target (100% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00214032 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00214032 about?
NCT00214032 is a clinical study titled "Pycnogenol for the Treatment of Lymphedema". The objectives of this study are to evaluate the effectiveness of Pycnogenol (French maritime pine bark extract) for arm lymphedema in women following treatment for breast cancer, to evaluate the accuracy and sensitivity of bioelectric impedence as a measurement of lymphedema of the arm, and to vali...
What is the current status of trial NCT00214032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2002-05. Estimated completion is 2007-01.
What conditions does trial NCT00214032 study?
This clinical trial studies the following conditions: Lymphedema.
What interventions are being tested in trial NCT00214032?
The interventions under investigation include: Placebo (DRUG), Pycnogenol (DRUG).
Who is sponsoring clinical trial NCT00214032?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00214032 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
RECRUITING · Phase 2
-
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
RECRUITING · Phase 2
-
Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
COMPLETED · Phase 2
-
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
COMPLETED · Phase 2
-
Lymphedema Surveillance Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.